Hi slick
the harsh, crappy truth is that at $600M mcap and still in the clinic the SP is probably fair value. Whilst in 2021 there were many pre revenue companies at multi B valuations, we are in a different world. Look at lke,nvx,peak msb... Not having a dig as I think immuno has a major role in future cancer care, but the mcap has major resistance imo until a clear path to revenue and drug submissions to FDA.
Cheers
Why IMU is a multi multi bagger, page-23173
-
- There are more pages in this discussion • 3,609 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
-0.002(4.00%) |
Mkt cap ! $356.9M | |||
| Open | High | Low | Value | Volume |
| 5.0¢ | 5.0¢ | 4.7¢ | $2.298M | 47.86M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 1925982 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 3452098 | 12 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |